Results 41 to 50 of about 6,750 (143)

Psoríase palmo-plantar: um estudo clínico epidemiológico [PDF]

open access: yes, 2006
Trabalho de Conclusão de Curso - Universidade Federal de Santa Catarina. Curso de Medicina.
Barros, Antonio Antunes da Cruz
core  

Refractory Palmoplantar Pustulosis Successfully Treated with JAK Inhibitor Tofacitinib: A Case Series

open access: yesInfection and Drug Resistance, 2023
Qingqing Xu,1 Xiaochen Wang,2 Anbo Yang,3 Guo Wei1 1Department of Dermato-Venereology, the Second Hospital of Shandong University, Jinan, 250033, People’s Republic of China; 2Clinical Laboratory of Qingdao Municipal Hospital, Qingdao, 266000, People’s ...
Xu Q, Wang X, Yang A, Wei G
doaj  

Nomenclature on Immune‐Mediated Drug Reactions: An EAACI Position Paper

open access: yesAllergy, EarlyView.
ABSTRACT Over the past several decades, there have been significant advances in our understanding of both immunological and pharmacological mechanisms of adverse drug reactions (ADRs). Immune‐mediated drug reactions (IMDRs) represent a small proportion of ADRs and are caused by a pathological activation of the immune system or inflammatory pathways ...
Maria J. Torres   +19 more
wiley   +1 more source

Pustulotic arthro-osteitis (Sonozaki Syndrome)

open access: yesIndian Journal of Dermatology, 2011
Pustulotic arthro-osteitis, first described by Sonozaki, is a relatively rare disorder. Its prevalence is however probably underestimated in dermatological literature. Early recognition of the signs can prevent misdiagnosis. We describe a Turkish patient
Ozlem Su   +4 more
doaj   +1 more source

Safety and pharmacokinetics of anumigilimab for hidradenitis suppurativa or palmoplantar pustulosis: A phase 1b study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Anumigilimab, a novel anti‐G‐CSF receptor antibody, was investigated in a phase 1b trial involving 39 patients with hidradenitis suppurativa or palmoplantar pustulosis. No serious safety concerns related to anumigilimab were noted, and PK and PD were dose dependent.
Johannes S. Kern   +14 more
wiley   +1 more source

Cardiac structure and function in psoriasis: A cross‐sectional analysis of the PSOCADIA study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Individuals with well‐treated psoriasis exhibited a higher burden of myocardial dysfunction (GLS < 16%) compared with controls, independent of cardiometabolic comorbidity. The prevalence was similar across psoriasis severity, highlighting the importance of cardiovascular assessment in all patients with psoriasis. Abstract Background Psoriasis is linked
Maria Dons   +16 more
wiley   +1 more source

Postpartum lumbopelvic pain could be SAPHO syndrome: a case report

open access: yesFrontiers in Immunology
BackgroundSynovitis–acne–pustulosis–hyperostosis–osteitis (SAPHO) syndrome is a rare autoimmune disorder. The involvement of spinal and sacroiliac joint in SAPHO syndrome closely resembles the manifestations of postpartum lumbopelvic pain (LPP).Case ...
Zheng Weiwei, Zhang Junhong, Zhang Rong
doaj   +1 more source

Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema

open access: yesAllergy, Volume 81, Issue 8, Page 2815-2832, August 2026.
This study performed an unbiased molecular profiling of CHE patients across diverse etiologies to identify shared pathogenic drivers and evaluate the impact of IL‐4Rα blockade via dupilumab over 16 weeks. CHE shows a mixed immune signature involving type 1, 2, and 3 pathways with features of atopic dermatitis and psoriasis.
Perrine Gery   +25 more
wiley   +1 more source

SAPHO Syndrome Presenting With Severe Inflammatory Back Pain (Sacroiliitis) and Rare Retinol Associated Myopathy in an Iraqi Adolescent Male: A Case Report and Literature Review

open access: yesClinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT SAPHO syndrome is a rare autoinflammatory disorder characterized by synovitis, acne, pustulosis, hyperostosis, and osteitis. Although musculoskeletal and dermatologic manifestations are well recognized, extra‐articular involvement remains uncommon, particularly muscular inflammation.
Farah Jaafar Mahdi   +7 more
wiley   +1 more source

Assessing the Effect of Adalimumab in Granuloma Annulare: A Case Series and Literature Review

open access: yesJEADV Clinical Practice, Volume 5, Issue 2, Page 651-655, June 2026.
ABSTRACT Granuloma annulare (GA) is a benign granulomatous skin disorder for which standardized treatment guidelines are lacking due to limited evidence. Adalimumab, a TNF‐α inhibitor, shows promise as a therapeutic option due to its potential to disrupt GA granulomas.
Adriana Caixinha Valorenzos   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy